Fusion Pharmaceuticals Inc (FUSN)

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens;...  and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada. As of June 4, 2024, Fusion Pharmaceuticals Inc. operates as a subsidiary of AstraZeneca AB.  और पढ़ें

• Founder, CEO & Director

  Dr. John F. Valliant Ph.D.

• Founder, CEO & Director

  Dr. John F. Valliant Ph.D.

• हेडक्वार्टर्स

  Hamilton, ON

• वेबसाइट

  https://www.fusionpharma.com